Lexicon Pharmaceuticals | LXRX - Ebitda





Ebitda Alterar Data
Abbott USD 3.27B 178M 2025-12
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 12.14B 4.26B 2025-12
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
Illumina USD 469M 137M 2025-12
Insmed USD -148.3M 165.88M 2026-03
Ironwood Pharmaceuticals USD 81.81M 31.71M 2025-09
J&J USD 7.19B 2.32B 2025-12
Lexicon Pharmaceuticals USD -12.04M 15.95M 2025-09
MacroGenics USD 21.95M 55.39M 2025-09
MannKind USD -3.05M 20.97M 2025-12
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Novartis USD 5.3B 530M 2026-03
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Thermo Fisher Scientific USD 2.7B 464M 2026-03
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
United Therapeutics USD 379.5M 83.4M 2025-12
Vanda Pharmaceuticals USD -8.31M 2.37M 2024-12